Outcomes4Me Acquires Geno.Me and Realyze Intelligence
May 21, 2026
Outcomes4Me, a direct-to-patient AI cancer care platform, completed its acquisitions of Geno.Me and Realyze Intelligence to expand its AI-driven cancer treatment and clinical trial access capabilities. Geno.Me provides patient data access and secure sharing via major EHR integrations, while Realyze Intelligence uses AI to abstract medical records into structured oncology data models for faster clinical trial matching.
- Buyers
- Outcomes4Me Inc.
- Targets
- Geno.Me, Realyze Intelligence
- Industry
- Healthcare Services
- Location
- United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Kailo Medical Acquires REI AI
May 21, 2025
AI & Machine Learning
Kailo Medical, a Melbourne-based provider of structured reporting and healthcare interoperability solutions, has acquired REI AI, a clinician-founded generative AI start-up focused on radiology reporting. The acquisition brings generative reporting capabilities into Kailo's product suite and appoints REI AI founder Dr. Reuben Schmidt as Director of Clinical AI to accelerate integration and clinical adoption.
-
QIAGEN Acquires Genoox
May 12, 2025
Biotechnology
QIAGEN has signed a definitive agreement to acquire Genoox, the developer of the AI-powered Franklin clinical genomics platform, for $70 million in cash plus up to $10 million in milestone payments. The acquisition adds Genoox's cloud-based AI interpretation capabilities to QIAGEN Digital Insights, expanding QIAGEN's clinical genomics and diagnostic software offerings for labs and healthcare organizations worldwide.
-
Carta Healthcare Acquires Realyze Intelligence from UPMC Enterprises
December 9, 2024
Healthcare Services
Carta Healthcare has acquired Realyze Intelligence, a UPMC Enterprises portfolio company. The deal brings Realyze's clinician-trained AI for rapid EHR-based oncology trial matching and data abstraction into Carta's AI-powered clinical data platform to accelerate clinical trial matching and registry abstraction.
-
Veracyte to Acquire C2i Genomics to Add Whole-Genome MRD Capabilities
January 8, 2024
Healthcare Services
Veracyte has reached a definitive agreement to acquire C2i Genomics, a minimal residual disease (MRD) detection company, to add whole-genome MRD capabilities to its diagnostics platform. Under the terms, Veracyte will pay $70 million in Veracyte shares at closing and up to an additional $25 million tied to future performance milestones, expected to close in the first quarter of 2024.
-
healthŌme Acquires Kailos Genetics
May 31, 2023
Biotechnology
healthŌme Inc. has acquired Kailos Genetics, a CLIA-certified and CAP-accredited genetic testing laboratory, making Kailos a wholly-owned subsidiary to expand healthŌme's genomics testing capabilities. The deal integrates Kailos' laboratory facilities, proprietary sequencing workflow and reagent supply capabilities into healthŌme's precision health management platform, expanding distribution into life and critical illness insurance channels and broader healthcare and life-science markets.
-
Genalyte Acquires BaseHealth
March 12, 2020
Healthcare Services
Genalyte acquired BaseHealth, a Bay Area healthcare data analytics company, effective March 12, 2020. The deal combines Genalyte's point-of-care diagnostic lab services with BaseHealth's AI-driven analytics platform to deliver real-time diagnostic and population-health insights at the point of care.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.